Journal Comparisons10 min readUpdated Apr 27, 2026

Nature Medicine vs JAMA

Nature Medicine and JAMA are both elite medical journals, but Nature Medicine wants translational mechanism while JAMA wants broad clinical evidence.

Associate Professor, Clinical Medicine & Public Health

Author context

Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.

Journal fit

See whether this paper looks realistic for Nature Medicine.

Run the Free Readiness Scan with Nature Medicine as your target journal and see whether this paper looks like a realistic submission.

Find my best fitAnthropic Privacy Partner. Zero-retention manuscript processing.See sample reportOr find a better-fit journal in 30 seconds
Journal context

Nature Medicine at a glance

Key metrics to place the journal before deciding whether it fits your manuscript and career goals.

Full journal profile
Impact factor50.0Clarivate JCR
Acceptance rate<8%Overall selectivity
Time to decision~30 daysFirst decision
Open access APC~$11,690 USDGold OA option

What makes this journal worth targeting

  • IF 50.0 puts Nature Medicine in a visible tier — citations from papers here carry real weight.
  • Scope specificity matters more than impact factor for most manuscript decisions.
  • Acceptance rate of ~<8% means fit determines most outcomes.

When to look elsewhere

  • When your paper sits at the edge of the journal's stated scope — borderline fit rarely improves after submission.
  • If timeline matters: Nature Medicine takes ~~30 days. A faster-turnaround journal may suit a grant or job deadline better.
  • If OA is required: gold OA costs ~$11,690 USD. Check institutional agreements before submitting.
Quick comparison

Nature Medicine vs JAMA at a glance

Use the table to see where the journals diverge before you read the longer comparison. The right choice usually comes down to scope, editorial filter, and the kind of paper you actually have.

Question
Nature Medicine
JAMA
Best fit
Nature Medicine published by Nature is one of the most selective medical research.
JAMA is one of the most widely read clinical journals in the world, with an impact.
Editors prioritize
Medical advance with clear human health or clinical impact
Immediate clinical applicability
Typical article types
Research Article
Original Investigation, Research Letter
Closest alternatives
Cell, Science
NEJM, The Lancet

Quick answer: Choose Nature Medicine when the manuscript's lead story is translational mechanism with convincing human relevance. Choose JAMA when the lead story is broad clinical evidence, patient-care relevance, health policy, or practice-facing medicine. The impact factors are close enough that fit matters more than the number.

If you want a fast journal-fit read before submission, start with the AI manuscript review. For journal-specific preparation, read the Nature Medicine submission guide and JAMA submission guide.

Method note: this page uses Nature Medicine aims and metrics, JAMA author materials, JCR metric references, and Manusights journal-fit review patterns reviewed in April 2026. This is the canonical comparison page; do not also build jama-vs-nature-medicine.

Head-to-head comparison

Question
Nature Medicine
JAMA
Core editorial question
Does this translate biology or technology into human health insight?
Does this matter to a broad clinical readership?
Strongest paper
Mechanism plus human validation
Broad clinical, policy, diagnostic, or practice evidence
2024 JIF signal
50.0 reported by Nature Medicine
55.0 commonly cited for JCR 2024
Best audience
Translational scientists and clinical researchers
Clinicians, clinical researchers, health systems readers
Common fit mistake
Clinical data are decorative
Paper is too mechanistic or specialty-narrow
Better first page
Mechanism-to-human bridge
Practice, patient, or health-system consequence

These journals are close in prestige but different in editorial instinct.

Choose Nature Medicine If / Choose JAMA If

Choose Nature Medicine if the manuscript's first-page promise is translational. The reader should see a biological, technological, biomarker, or disease-mechanism story that becomes more convincing because it is tied to human health.

Choose JAMA if the first-page promise is clinical. The reader should see a question that matters across medicine, affects practice or interpretation, and can be understood without making mechanism the main event.

This is the cleanest way to avoid cannibalization between comparison pages. Nature Medicine vs JAMA is not a generic "top medical journal" page. It is a decision page for authors choosing between translational prestige and broad clinical reach.

Journal fit

Ready to find out which journal fits? Run the scan for Nature Medicine first.

Run the scan with Nature Medicine as the target. Get a fit signal that makes the comparison concrete.

Find my best fitAnthropic Privacy Partner. Zero-retention manuscript processing.See sample reportOr find a better-fit journal in 30 seconds

The Simple Decision

If the paper explains why a disease process, therapy, technology, or biomarker matters in humans, Nature Medicine is usually the cleaner target.

If the paper tells clinicians, guideline writers, policy readers, or health-system researchers something they can act on or interpret broadly, JAMA is usually the cleaner target.

Manuscript lead story
Better first target
Disease mechanism with human validation
Nature Medicine
Randomized clinical study with broad practice relevance
JAMA
Biomarker tied to translational biology
Nature Medicine
Screening, diagnostic, population, or health-policy evidence
JAMA
Early clinical trial with mechanism-rich companion data
Nature Medicine
Clinical finding aimed mainly at one subspecialty
JAMA specialty journal or top specialty venue

If the lead story is unclear, fix the abstract before choosing the journal.

What Nature Medicine Wants

Nature Medicine's aims and scope state that it considers translational and clinical research based on originality, timeliness, and impact on improving human health. It covers clinical trials, observational studies, meta-analyses, biomarker studies, public health studies, and hybrid studies that combine preclinical and clinical findings.

That breadth is not an invitation to send every clinical paper. Nature Medicine is strongest when the manuscript builds a bridge between mechanism and human health.

What JAMA Wants

JAMA positions itself around original, important, valid, peer-reviewed articles across medicine. In practice, it is strongest when the paper has broad clinical relevance, readable framing, strong reporting, and a clear reason for a general medical audience to care.

JAMA is often more natural than Nature Medicine when the manuscript's value is:

  • clinical practice evidence
  • population health
  • health policy
  • screening or diagnostic evidence
  • outcomes research
  • patient-care relevance across specialties

The paper does not need a deep mechanistic story if the clinical question is broad enough.

In Our Pre-Submission Review Work

In our pre-submission review work, Nature Medicine vs JAMA decisions usually fail because authors choose the more prestigious-sounding fit rather than the reader fit.

Translational paper aimed at JAMA: the clinical condition matters, but the manuscript's real contribution is mechanism, biomarker biology, or technology. JAMA readers may see a paper that takes too long to reach a practice consequence.

Clinical paper aimed at Nature Medicine: the result matters for patients or systems, but the mechanistic bridge is thin. Nature Medicine editors may see an excellent clinical paper that belongs in a clinical journal.

Metric-first targeting: authors compare JIF and ignore the first page. That is the wrong decision rule.

Nature Medicine Failure Patterns

Nature Medicine gets harder when:

  • the human dataset is small or decorative
  • the clinical result is practice-facing but not mechanistic
  • the translational bridge appears late
  • the paper feels like a clinical trial with a thin biomarker add-on
  • the first figure does not show why human biology is changing

The manuscript has to look designed for a translational audience from the beginning.

JAMA Failure Patterns

JAMA gets harder when:

  • the best audience is a narrow specialty community
  • the main result requires technical biology before the clinical meaning appears
  • the evidence is interesting but not broadly useful
  • the abstract overstates clinical actionability
  • the paper is really a Nature Medicine-style mechanistic bridge

JAMA fit is not just "medical topic." It is broad clinical relevance.

Practical Targeting Matrix

Manuscript pattern
Better target
Phase 1 trial with deep biomarker mechanism
Nature Medicine
Pragmatic clinical trial with broad practice relevance
JAMA
Pan-disease biomarker biology
Nature Medicine
Health-system intervention study
JAMA
AI model revealing disease biology
Nature Medicine
AI model improving clinical workflow or diagnosis
JAMA or JAMA specialty journal
Public health study with practice relevance
JAMA
Hybrid preclinical and clinical package
Nature Medicine

The question is not "which journal is better?" It is "which editor sees the manuscript's value fastest?"

What To Fix Before Submission

For Nature Medicine, make the mechanism-to-human bridge visible in the title, abstract, first figure, and cover letter. The clinical data should not feel like a final validation panel added to a basic science paper.

For JAMA, make the clinical consequence visible in the title, structured abstract, and first table or figure. The reader should not need to understand every molecular detail to see why the result matters.

Submit If / Think Twice If

Submit to Nature Medicine if:

  • the manuscript has a real translational bridge
  • human relevance is demonstrated, not decorative
  • the strongest audience includes translational scientists
  • clinical data and biology support one argument

Submit to JAMA if:

  • the manuscript matters to a broad clinical audience
  • the result is readable and practice-facing
  • reporting and study design are already clean
  • the paper does not need a mechanistic explanation to matter

Think twice for both if:

  • the paper is mainly a specialty result
  • the first page cannot name the audience
  • the target is chosen by impact factor alone

Bottom Line

Nature Medicine and JAMA are close enough in metric prestige that the decision should be editorial. Nature Medicine wants translational mechanism with human relevance. JAMA wants broad clinical evidence a medical audience can use.

Use the AI manuscript review if you need a fast read on which journal your first page actually supports.

Frequently asked questions

Submit to Nature Medicine when the strongest story is translational mechanism with human relevance. Submit to JAMA when the strongest story is broad clinical evidence, health policy, or practice-relevant medicine.

JAMA is commonly cited at a 2024 JCR impact factor of 55.0, while Nature Medicine reports a 2024 JIF of 50.0. The difference should not decide journal fit.

Yes, if the clinical trial carries mechanistic, biomarker, or translational insight. A trial whose main value is practice evidence is usually a better fit for JAMA or another clinical journal.

The two pages would answer the same comparison query. Manusights uses one canonical comparison page to avoid cannibalization.

References

Sources

  1. https://www.nature.com/nm/aims
  2. https://www.nature.com/nm/journal-impact
  3. https://jamanetwork.com/journals/jama/pages/for-authors
  4. https://jamanetwork.com/journals/jama/pages/instructions-for-authors
  5. https://jcr.clarivate.com/

Final step

See whether this paper fits Nature Medicine.

Run the Free Readiness Scan with Nature Medicine as your target journal and get a manuscript-specific fit signal before you commit.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next

Find my best fit